ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Fiche publication
Date publication
janvier 2015
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ
Lien Pubmed
Résumé
Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during interferon-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown. We examined the relationship between two ITPA polymorphisms, anemia, and sustained virological response 12 weeks post-treatment (SVR12) in patients receiving the NS3/4A protease inhibitor faldaprevir, the non-nucleoside polymerase inhibitor deleobuvir, and ribavirin.
Mots clés
Acrylates, pharmacology, Anemia, diagnosis, Antiviral Agents, pharmacology, Benzimidazoles, pharmacology, Female, Genotype, Hepacivirus, drug effects, Hepatitis C, complications, Humans, Interferons, metabolism, Male, Middle Aged, Oligopeptides, pharmacology, Polymorphism, Single Nucleotide, genetics, Pyrophosphatases, genetics, Real-Time Polymerase Chain Reaction, Ribavirin, pharmacology, Thiazoles, pharmacology
Référence
PLoS ONE. 2015 ;10(12):e0144004